IQVIA Holdings Inc. (NYSE:IQV) Stake Lifted by 2Xideas AG

2Xideas AG raised its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 14.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 225,423 shares of the medical research company's stock after purchasing an additional 28,624 shares during the quarter. IQVIA comprises approximately 5.9% of 2Xideas AG's portfolio, making the stock its 4th largest holding. 2Xideas AG owned about 0.12% of IQVIA worth $44,298,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in IQV. Synergy Asset Management LLC acquired a new position in IQVIA in the 4th quarter valued at about $33,000. Lee Danner & Bass Inc. acquired a new position in shares of IQVIA in the fourth quarter valued at approximately $44,000. Zions Bancorporation N.A. raised its stake in shares of IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after purchasing an additional 85 shares during the last quarter. Versant Capital Management Inc lifted its holdings in shares of IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after purchasing an additional 93 shares during the period. Finally, SBI Securities Co. Ltd. purchased a new position in IQVIA in the 4th quarter valued at $60,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

Shares of NYSE IQV traded up $2.46 during trading on Friday, reaching $145.68. The company had a trading volume of 1,163,285 shares, compared to its average volume of 1,374,061. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market capitalization of $25.69 billion, a PE ratio of 19.25, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a twelve month low of $135.97 and a twelve month high of $252.88. The stock has a 50-day moving average price of $183.41 and a two-hundred day moving average price of $200.24.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on IQV. UBS Group cut their price objective on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Morgan Stanley raised their price objective on shares of IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Truist Financial dropped their target price on IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research report on Thursday. BTIG Research cut IQVIA from a "buy" rating to a "neutral" rating in a report on Monday, February 3rd. Finally, JPMorgan Chase & Co. dropped their price objective on IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a report on Tuesday, February 18th. Six equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $241.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.